Multicenter observational study on the efficacy of selective Janus Kinase-1 inhibitor upatacitinib in rheumatoid arthritis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lo Gullo Alberto, Parisi Simone, Becciolini Andrea, Paroli Marino, Bravi Elena, Andracco Romina, Nucera Valeria, Ometto Francesca, Lumetti Federica, Farina Antonella, Del Medico Patrizia, Colina Matteo, Ravagnani Viviana, Scolieri Palma, Larosa Maddalena, Priora Marta, Visalli Elisa, Addimanda Olga, Vitetta Rosetta, Volpe Alessandro, Bezzi Alessandra, Girelli Francesco, Molica Colella Aldo Biagio, Caccavale Rosalba, DI Donato Eleonora, Adorni Giuditta, Santilli Daniele, Lucchini Gianluca, Arrigoni Eugenio, Platè Ilaria, Mansueto Natalia, Ianniello Aurora, Fusaro Enrico, Ditto Maria Chiara, Bruzzese Vincenzo, Camellino Dario, Bianchi Gerolamo, Serale Francesca, Foti Rosario, Amato Giorgio, DE Lucia Francesco, Dal Bosco Ylenia, Foti Roberta, Reta Massimo, Fiorenza Alessia, Rovera Guido, Marchetta Antonio, Focherini Maria C, Mascella Fabio, Bernardi Simone, Sandri Gilda, Giuggioli Dilia, Salvarani Carlo, DE Andres Maria Ilenia, Franchina Veronica, Molica Colella Francesco, Ferrero Giulio, Ariani Alarico
Аннотация
METHODS: A series of 111 consecutive patients treated with UPA in 23 rheumatology centers were enrolled. Personal history, treatment history and disease activity at baseline, after 6 and 12 months were recorded. Intention-to-treat (ITT) and per-protocol (PP) analyses assessed achievement of remission or LDA or defined as DAS28 <2.6 and ≤3.2, respectively. Logistic regression analysis examined the role of several independent factors on the reduction of disease activity after 6 months of treatment.
RESULTS: Of the initial group of 111 subjects at baseline, 86 and 29 participants completed clinical assessments at 6 and 12 months. According to ITT analysis, the rates of remission and LDA were 18% and 18% at 6 months and 31.5% and 12.5% at 12 months, respectively. PP analysis showed higher rates of remission and LDA at 6 (23.3% and 19.8%) and 12 months (55.2% and 20.7%). Results of multivariate logistic regression analysis indicated that a low DAS28 score (P=0.045) was the only predictor of achieving remission at 6 months. None of the baseline factors predicted remission/LDA at 6 months.
CONCLUSIONS: RA patients treated with UPA achieved a significant rate of disease remission or LDA in a real-world setting. The 6-month response was found to depend only on the baseline value of DAS28, while it was not influenced by other factors such as disease duration, line of treatment or concomitant therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or corticosteroids.